Effect of radiotherapy on expression of hyaluronan and EGFR and presence of mast cells in squamous cell carcinoma of the head and neck

  • Authors:
    • Eva Lindell Jonsson
    • Karin Nylander
    • Lars Hallén
    • Göran Laurell
  • View Affiliations

  • Published online on: September 11, 2012     https://doi.org/10.3892/ol.2012.907
  • Pages: 1177-1182
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Head and neck squamous cell carcinoma is a common form of cancer, and despite improvements in treatment during the last decades, survival rates have not significantly increased. There is therefore a need to better understand how these tumours and the adjacent tissues react to radiotherapy, the most common type of treatment for this group of tumours. In order to improve this understanding, the expression of hyaluronan (HA) and epidermal growth factor receptor (EGFR) and the presence of mast cells were mapped before and after radiotherapy using immunohistochemistry. The results showed HA and EGFR to have similar expression patterns in tumour tissue and histologically normal squamous epithelium prior to radiotherapy. Following radiotherapy, EGFR increased in histologically normal epithelium. An increased number of mast cells were also observed as a result of radiotherapy. No expression of EGFR was observed in the connective tissue either prior to or following radiotherapy.

Introduction

Squamous cell carcinoma of the head and neck (SCCHN) is the sixth most frequent type of cancer worldwide (1), with more than half a million new cases reported annually (2). The 5-year survival rate is approximately 50%, which is one of the lowest among the more common cancer types. Radiotherapy (RT) remains the major approach to curative treatment despite improvements in chemotherapy schedules (3,4), and it is therefore of interest to study how RT affects potential biomarkers such as those below.

Hyaluronan (HA) is a linear disaccharide polymer belonging to the family of glycosaminoglycans, which comprises the major fraction of carbohydrates in the extracellular matrix (ECM). The loose HA matrix provides a favourable environment for mitotic cells and is essential for numerous functions, including cell migration and tissue remodelling during the morphogenesis of organs. HA is also thought to enhance wound healing, tumour growth and metastasis (5). In SCCHN, HA mediates the formation of a complex between the receptor CD44 and the epidermal growth factor receptor (EGFR) (6) which is overexpressed in a large proportion of SCCHN cases (7).

EGFR is a transmembrane protein receptor that plays an essential role in regulating cellular processes such as proliferation, differentiation and survival, and is also central to the maintenance of normal epidermal tissue, where its expression is highly regulated (8,9). When deregulated, EGFR aids in the growth and survival of cancer cells, and is therefore an important target in cancer therapy using monoclonal antibodies (10). EGFR-mediated pathways are involved in the HA/CD44 promotion of chemoresistance in SCCHN (11).

Mast cells are among the first of several immunological cell types migrating to the site of tissue damage, e.g. radio-induced tissue injury. Mast cells cause inflammation by secreting reactive oxygen species, vasoactive molecules, cytokines, chemokines and proteases that remodel the ECM (12). SCCHN tumours, however, have shown a lower number of mast cells than squamous cell carcinoma tumours in other locations (13).

In order to further map the effect of RT in SCCHN we explored the expression of HA and EGFR and presence of mast cells in tumours and adjacent tissue before and after RT.

Materials and methods

Study population

Sixteen patients with SCCHN treated at the Departments of Otolaryngology and Head and Neck Surgery and Oncology, Umeå University Hospital (Umeå, Sweden) between 2001 and 2009 were included. Patients were selected from a larger cohort of patients with the inclusion criteria that they had undergone RT and also had biopsies before and after treatment. Medical records were reviewed and relevant clinical data recorded, including survival, age, tumour site and stage. All patients had at least two years of follow-up (Table I). Informed consent was obtained from the patients prior to the study.

Table I.

Patient characteristics.

Table I.

Patient characteristics.

Patient numberSiteTNM DifferentiationIrradiation (Gy)SurgeryResidual tumourAge at diagnosis (years)Gender2-year survival
1Piriform sinusT4N3M0Poor68NoNo70MNo
2Palatine archT2N2cM0Moderate68YesNo59MYes
3GingivaT4N1M0Moderate68NoNo51MYes
4GingivaT4N2bM0Moderate68NoNo80FYes
5Hard palateT4N0M0Moderate68YesNo63MYes
6GingivaT4N2bM0Moderate68NoNo83MYes
7BuccaT4N0M0Poor68YesYes85FYes
8TongueT4N0M0Poor68NoNo48MYes
9TongueT4N2bM0Poor68NoNo43MNo
10GingivaT4N1M0Moderate68YesNo73FYes
11TongueT2N0M0Poor68YesNo74MYes
12TongueT4N2cM0Poor68NoNo61MYes
13Palatine archT3N2bM0Moderate68NoNo52MYes
14Floor of mouthT4N2bM0Moderate68YesNo78FNo
15TonsilT2N2cM0Poor68YesNo53MYes
16TongueT4aN0M0Moderate66NoNo70MYes

In general, treatment for SCCHN was based on the TNM classification, stage and patient performance. All patients were discussed at a multidisciplinary conference and treatment was given with curative intent.

Patients received RT from a linear accelerator in one daily fraction of 2 Gy 5 days a week, with a mean total dose of 68 Gy.

Seven of the patients received combined modality treatment (preoperative RT followed by surgical resection) and 9 patients single modality RT. The latter 9 patients showed clinical complete response and underwent endoscopic examination at regular intervals to assess the outcome of RT including biopsy of the tumour region for histopathological examination.

Immunohistochemistry

Archival paraffin blocks were cut into 5-μm sections and analysed using immunohistochemistry. Staining for HA was performed according to Hellström et al (14). In brief, endogenous peroxidase activity was quenched by incubation in 3% H2O2 in phosphate-buffered saline (PBS) for 5 min at room temperature. Non-specific binding was then blocked with 1% bovine serum albumin followed by incubation with 100 μl biotinylated HA binding protein (HABP) diluted at a concentration of 1:40 overnight at 4°C. The Vectastain Elite avidin-biotin complex reagent was then used according to the manufacturer’s instructions (Vector Laboratories, Burlingame, CA, USA) together with the diaminobenzidine (DAB) substrate kit (Vector Laboratories). Slides were counterstained with Mayer’s haematoxylin. Control slides were incubated with 50 U/ml of Streptomyces hyaluronidase (Sigma, St. Louis, MO, USA), which specifically degrades hyaluronan, for 4 h at 37°C.

For the detection of EGFR, a monoclonal anti-EGFR antibody (Dako, clone E30) diluted at 1:50 was used. This antibody reacts with an external domain present in the transmembrane 170 kDa protein of both the wildtype EGFR and the EGFRvIII variant. For the detection of mast cells, an antibody recognising tryptase (Dako, clone AA1) diluted at 1:100 was used. The Ventana ES autostainer (Ventana, Tucson, AZ, USA) was used according to the manufacturer’s recommendations.

Assessment

All histological samples were reviewed and the grade of differentiation was evaluated by one of the authors (K.N.) who was blinded to the clinical outcome. Two independent scorers (co-authors E.L.J. and K.N.) assessed the slides stained for EGFR and tryptase, and three independent scorers (co-authors E.L.J., K.N. and L.H.) assessed the slides stained for HA.

Staining results for HA were scored in histologically normal epithelium, connective tissue and tumour tissue. Scores representing the percentage of tissue positive for HA were as follows: 0, no staining; 1, 1–25% of the tissue stained; 2, 26–50% stained; 3, 51–75% stained and 4, 76–100% stained. Staining intensity was scored as 0, no staining; 1, weak staining; 2, moderate staining and 3, strong staining. Cellular localisation of HA was further scored as pericellular (PC), intra- and pericellular (IPC), or intracellular (IC), as adapted from Melrose et al (15).

EGFR was scored according to Kersemaekers et al (16) examining histologically normal epithelium and tumour tissue. The percentage of cells stained as well as the intensity of staining were scored the same way as for HA. The density of tryptase-expressing cells in histologically normal epithelium, connective tissue and tumour was scored in the whole biopsies or surgical specimens and the mean from two independent scorers was calculated.

Ethical considerations

The study was approved by the University of Umeå Institutional Review Board (registration numbers 01-057 and 03-201).

Results

Fifteen of the 16 patients showed clinical complete response, and the remaining patient showed partial response. The overall 2-year survival was 81% (13 of 16 patients). The median time between RT and surgery was 53 days (range, 40–369) with one outlier who was not initially intended for surgery, while the median time between RT and control biopsy was 75 days (range, 42–305) as the patients undergoing endoscopic examination were not biopsied at fixed intervals, only when a suspected lesion was found during endoscopy.

Immunohistochemistry

Pre-RT biopsies were available for all 16 patients, and were stained for EGFR, HA and tryptase. Two biopsies were excluded from staining with HA and EGFR, and one from staining with tryptase due to a limited amount of tumour tissue for proper evaluation. The amount of connective tissue was limited in many of the pre-RT biopsies but there was sufficient in all samples for evaluation. Seven surgical specimens and nine control biopsies post-RT were available for EGFR, HA and tryptase analyses. A viable tumour was only observed in one specimen following RT treatment.

Expression of HA

In the 12 biopsies with histologically normal epithelium, HA was mainly localised in the cell layers close to the basal lamina, whereas the more suprabasal layers were negative. HA staining was more intracellular (IC) in the basal and parabasal layers and pericellular (PC) in the more superficial layers (Fig. 1). No biopsies demonstrated IC staining, whereas six biopsies demonstrated PC staining. All tumours expressed HA with more intense staining observed in less differentiated tumours; this was similar to HA staining in the basal layers of histologically normal epithelium prior to RT. Two biopsies with poorly differentiated SCC demonstrated IC staining, whereas the remaining 14 tumours demonstrated IPC staining. The localization of HA in histologically normal epithelium was not significantly affected by RT (Fig. 1); the number of cases scored as PC or IPC, and the part of epithelium stained were not affected by RT.

In the connective tissue, increased expression of HA was observed post-RT, and the number of cases where the whole connective tissue expressed HA also increased (Fig. 1). In the case with a remaining viable tumour no change in HA expression was observed.

Expression of EGFR

Expression of EGFR in histologically normal epithelium was similar to HA expression in the most basal cell layers, and less intense in the more superficial and more differentiated layers. EGFR also appeared to be intracellularly located in the more basal layers of the epithelium. All tumours also expressed EGFR, with more intense expression observed in less differentiated tumours. Twelve of the 16 specimens demonstrated the highest proportion of staining (76–100%), and staining was more intense in tumours compared to histologically normal epithelium (Table II). None of the biopsies demonstrated EGFR staining in the connective tissue.

Table II.

Changes in the staining patterns induced by radiotherapy (RT).

Table II.

Changes in the staining patterns induced by radiotherapy (RT).

Pre-RT
Post-RT
TissueHAEGFRTryptaseHAEGFRTryptase
Histologically normal epitheliumAll samples + Basal or parabasal cell layersAll samples + Basal or parabasal cell layersAll samples All samples + Basal or parabasal cell layersAll samples + Basal or parabasal cell layersFew Basal or parabasal cell layers
Connective tissueAll samples +All samples All samples +All samples +All samples All samples +
TumourAll samples + Differentiation staining All samples + Differentiation staining All samples +Remaining tumour +Remaining tumour +Remaining tumour +

+, positive staining;

−, negative staining;

↑, increase in staining;

↓, decrease in staining;

→, leads to.

The percentage of EGFR-expressing cells in histologically normal epithelium increased following RT. However, RT did not induce EGFR expression in the connective tissue. In the specimen containing a viable tumour following RT, neither the intensity nor the percentage of EGFR-expressing cells changed but still scored highest in their category.

Presence of mast cells

Mast cells could in general be observed throughout the connective tissue, whereas almost no mast cells (mean count, 1.3) were observed in normal epithelium, and five samples were completely devoid. The few mast cells present in the epithelium pre-RT were located basally. Conversely, mast cells were observed infiltrating tumours with a mean count of 2.0 tryptase-expressing cells in pre-RT samples compared to 1.3 in normal epithelium.

The mean count of tryptase-expressing cells in histologically normal epithelium increased from 1.3 to 2.0 post-RT, whereas the mean count in the connective tissue decreased from 18.0 to 11.0 post-RT. The increases and decreases are shown in Table II. In the specimen with viable tumour tissue following RT, tryptase-expressing cells decreased from 10.2 to 3.3.

Discussion

Radiotherapy (RT) remains the main choice of treatment for most patients with SCCHN, either as a single modality treatment or combined with surgery. In order to improve treatment there is a need to better understand how SCCHN and adjacent tissues react to RT, and which side effects the treatment may have. In the present study, the expression of HA and EGFR and the presence of mast cells were studied in biopsies and surgical specimens before and after RT. HA and EGFR showed similar expression patterns before RT both in tumour and histologically normal epithelium. The less differentiated the tumour was, the more intense the staining of both HA and EGFR, a staining pattern similar to that observed in the more basal layers of normal epithelium. This is in accordance with previous results (7,17), and proposed to be due to the role of HA in cell proliferation (18). Earlier studies have shown that staining intensity correlates with the expression of HA (19). Our results confirm the earlier findings of cytoplasmic HA and EGFR, although their role in the cytoplasm is still unclear (20). Membranous staining of EGFR has been shown in clinical studies to correlate with cervical lymph node metastases and survival (21,22). The major ligand for EGFR, EGF, induces migration in connective tissue-derived cells (23). It has been shown that RT induces migration in SCCHN cells in vitro, something that is inhibited when EGFR is blocked, suggesting a connection between the mechanisms (24). In vitro studies have shown expression of EGFR in connective tissue fibroblasts (25,26), something we could not confirm in the present study either before or after RT. The HA and EGFR-correlated receptor CD44 is also known to be expressed by fibroblasts, and higher HA concentration in cell cultures induces less cell proliferation but more migration in fibroblasts (27).

HA is not, as was earlier believed, just a passive molecule in the ECM but is capable of interacting with ECM macromolecules and cell surface receptors, including CD44 (28). The complex molecular mechanism, including the promotion of CD44/EGFR interaction and EGFR-mediated oncogenic signalling (29), makes it even more significant to analyse a connection between these two markers. Both EGFR and HA overexpression in tumours has been linked to poorer prognosis (30). Our results, in accordance with previous results, showed stronger EGFR staining in tumour tissue compared to normal epithelium (7). We also observed that EGFR staining intensity in normal epithelium increased post-RT, although not to the same level as in tumour tissue pre-RT. The only case with no clinical response/partial response to RT showed the highest EGFR score both before and after RT. This is in accordance with earlier findings that high EGFR expression is correlated with a reduced cellular response to RT (31). Due to its role in cell signalling, EGFR is considered both a predictive marker and a target for cancer therapy. EGFR inhibitors such as C225 (Cetuximab™), a monoclonal antibody to the extracellular domain, have shown radiosensitivity enhancement with amplification of radiation-induced apoptosis in tumour specimens (32). Irradiation is known to induce structural alterations of HA such as degradation (33) and cause alteration of the physical properties; however, to which extent, is yet unknown. HA fragments are further released by most solid tumour cells and activate inflammatory cell signalling, promoting tumour motility (34). In the present study, however, we did not detect any changes in HA expression in normal epithelium or in the one sample with viable tumour cells following RT. A decrease in mast cells was observed post-RT in the connective tissue, but with no correlation to the interval between termination of RT and the time of biopsy or surgical procedure. A minor increase in mast cells in the epithelium was found following RT, and the tumour remaining following RT was also surrounded by an abundance of mast cells, in accordance with animal studies demonstrating an influx of mast cells during RT (33,34). There is an established correlation between chronic inflammation and cancer (35) and mast cells are known to contribute to pre-malignant progression (3639). It is known from animal models that mastocytosis in irradiated lung tissue is followed by increased deposition of HA (40,41), which is known to affect the lymphocytic response (42). Our finding that HA was expressed more intensely in the connective tissue stroma post-RT could most probably be viewed as a result of the fibrosis caused by irradiation. This is supported by studies having suggested a possible role for mast cells in fibrosis as a late effect of RT (41).

In conclusion, we have shown RT to have an effect on the expression of HA and EGFR as well as the presence of mast cells in SCCHN tumours. These tumours are, however, known to be heterogeneous (43); therefore, in order to properly evaluate the effect of RT in SCCHN tumours, the tumours should be divided based on subsites in future studies.

Acknowledgements

We gratefully thank Cathrine Johansson and Astrid Höglund for their skilful technical assistance. This study was supported by grants from the Lion’s Cancer Research Foundation, Umeå University, and the Acta Otolaryngologica Foundation.

References

1. 

D MurdochStandard, and novel cytotoxic and molecular-targeted, therapies for HNSCC: an evidence-based reviewCurr Opin Oncol19216221200710.1097/01.cco.0000264952.98166.9917414639

2. 

ES KimM KiesRS HerbstNovel therapeutics for head and neck cancerCurr Opin Oncol14334342200210.1097/00001622-200205000-0001411981281

3. 

BP TooleHyaluronan in morphogenesisSemin Cell Dev Biol127987200110.1006/scdb.2000.0244

4. 

P HeldinE KarousouB BernertH PorschK NishitsukaSS SkandalisImportance of hyaluronan-CD44 interactions in inflammation and tumorigenesisConnect Tissue Res49215218200810.1080/0300820080214332318661346

5. 

MA SimpsonJA WeigelPH WeigelSystemic blockade of the hyaluronan receptor for endocytosis (HARE) prevents lymph node metastasis of prostate cancerInt J Cancer131E836E840201210.1002/ijc.2742722234863

6. 

SJ WangLY BourguignonHyaluronan and the interaction between CD44 and epidermal growth factor receptor in oncogenic signaling and chemotherapy resistance in head and neck cancerArch Otolaryngol Head Neck Surg132771778200610.1001/archotol.132.7.77116847188

7. 

T EkbergM NestorM EngströmH NordgrenK WesterJ CarlssonM AnnikoExpression of EGFR, HER2, HER3, and HER4 in metastatic squamous cell carcinomas of the oral cavity and base of tongueInt J Oncol2611771185200515809707

8. 

J MendelsohnJ BaselgaEpidermal growth factor receptor targeting in cancerSemin Oncol33369385200610.1053/j.seminoncol.2006.04.00316890793

9. 

O RiestererL MilasKK AngCombining molecular therapeutics with radiotherapy for head and neckJ Surg Oncol97708711200810.1002/jso.2101118493923

10. 

O DassonvilleJL FormentoM FrancoualA RamaioliJ SantiniM SchneiderF DemardG MilanoExpression of epidermal growth factor receptor and survival in upper aerodigestive tract cancerJ Clin Oncol111873187819938410112

11. 

LY BourguignonC EarleG WongCC SpevakK KruegerStem cell marker (Nanog) and Stat-3 signaling promote MicroRNA-21 expression and chemoresistance in hyaluronan/CD44-activated head and neck squamous cell carcinoma cellsOncogene31149160201210.1038/onc.2011.22221685938

12. 

SR JunankarA EichtenA KramerKE de VisserLM CoussensAnalysis of immune cell infiltrates during squamous carcinoma developmentJ Investig Dermatol Symp Proc113643200610.1038/sj.jidsymp.565002417069009

13. 

AC PariziRL BarbosaJL PariziGA NaiA comparison between the concentration of mast cells in squamous cell carcinomas of the skin and oral cavityAn Bras Dermatol85811818201021308304

14. 

S HellströmA TengbladC JohanssonU HedlundE AxelssonAn improved technique for hyaluronan histochemistry using microwave irradiationHistochem J2267768219901706695

15. 

J MelroseM TammiS SmithVisualisation of hyaluronan and hyaluronan-binding proteins within ovine vertebral cartilages using biotinylated aggrecan G1-link complex and biotinylated hyaluronan oligosaccharidesHistochem Cell Biol117327333200210.1007/s00418-002-0392-4

16. 

AM KersemaekersGJ FleurenGG KenterLJ Van den BroekSM UljeeJ HermansMJ Van de VijverOncogene alterations in carcinomas of the uterine cervix: overexpressionClin Cancer Res5577586199910100709

17. 

C WangM TammiH GuoR TammiHyaluronan distribution in the normal epithelium of esophagus, stomach, and colon and their cancersAm J Pathol1481861186919968669472

18. 

M InoueC KatakamiThe effect of hyaluronic acid on corneal epithelial cell proliferationInvest Ophthalmol Vis Sci342313231519938505213

19. 

C LaurentG Johnson-WellsS HellströmA Engström-LaurentAF WellsLocalization of hyaluronan in various muscular tissuesCell Tissue Res263201205199110.1007/BF003187612007249

20. 

M EricksonR SternChain gangs: new aspects of hyaluronan metabolismBiochem Res Int2012893947201210.1155/2012/89394722216413

21. 

A MahipalMJ McdonaldA WitkiewiczBI CarrCell membrane and cytoplasmic epidermal growth factor receptor expression in pancreatic ductal adenocarcinomaMed Oncol29134139201110.1007/s12032-010-9802-y21264542

22. 

MG NoordhuisJJ EijsinkKA Ten HoorExpression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancerClin Cancer Res1573897397200910.1158/1078-0432.CCR-09-1149

23. 

Q KongRJ MajeskaM VazquezMigration of connective tissue-derived cells is mediated by ultra-low concentration gradient fields of EGFExp Cell Res31714911502201110.1016/j.yexcr.2011.04.00321536028

24. 

AC PickhardJ MargrafA KnopfInhibition of radiation induced migration of human head and neck squamous cell carcinoma cells by blocking of EGF receptor pathwaysBMC Cancer11388201110.1186/1471-2407-11-38821896192

25. 

MD HollenbergP CuatrecasasEpidermal growth factor: receptors in human fibroblasts and modulation of action by cholera toxinProc Natl Acad Sci USA7029642968197310.1073/pnas.70.10.29644355377

26. 

G CarpenterKJ LembachMM MorrisonS CohenCharacterization of the binding of 125-I-labeled epidermal growth factor to human fibroblastsJ Biol Chem250429743041975

27. 

M YagiN SatoY MitsuiHyaluronan modulates proliferation and migration of rabbit fibroblasts derived from flexor tendon epitenon and endotenonJ Hand Surg Am35791796201010.1016/j.jhsa.2010.02.01020438995

28. 

CL ArteagaEpidermal growth factor receptor dependence in human tumors: more than just expression?Oncologist73139200210.1634/theoncologist.7-suppl_4-3112202786

29. 

SK BlickLJ ScottCetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancerDrugs6725852607200710.2165/00003495-200767170-0000818034592

30. 

K RopponenM TammiJ ParkkinenTumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancerCancer Res5834234719989443415

31. 

U Kasten-PisulaJ SakerW EichelerCellular and tumor radiosensitivity is correlated to epidermal growth factor receptor protein expression level in tumors without EGFR amplificationInt J Radiat Oncol Biol Phys8011811188201110.1016/j.ijrobp.2011.02.043

32. 

JA BonnerPM HarariJ GiraltRadiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survivalLancet Oncol1121282010

33. 

E DaarL KingA NisbetViscosity changes in hyaluronic acid: irradiation and rheological studiesAppl Radiat Isot68746750201010.1016/j.apradiso.2009.10.02219910202

34. 

Y WuQ ZhaoC PengNeutrophils promote motility of cancer cells via a hyaluronan-mediated TLR4/PI3K activation loopJ Pathol225438447201110.1002/path.294721826665

35. 

F BalkwillA MantovaniCancer and inflammation: implications for pharmacology and therapeuticsClin Pharmacol Ther87401406201010.1038/clpt.2009.31220200512

36. 

LM CoussensWW RaymondG BergersInflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesisGenes Dev1313821397199910.1101/gad.13.11.138210364156

37. 

D RibattiMG EnnasA VaccaTumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanomaEur J Clin Invest33420425200310.1046/j.1365-2362.2003.01152.x12760367

38. 

M SawatsubashiT YamadaN FukushimaAssociation of vascular endothelial growth factor and mast cells with angiogenesis in laryngeal squamous cell carcinomaVirchows Arch436243248200010.1007/s00428005003710782883

39. 

A ImadaN ShijuboH KojimaMast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinomaEur Respir J1510871093200010.1034/j.1399-3003.2000.01517.x10885428

40. 

K NilssonR HenrikssonS HellströmHyaluronan reflects the pre-fibrotic inflammation in irradiated rat lung: concomitant analysis of parenchymal tissues and bronchoalveolar lavageInt J Radiat Biol58519530199010.1080/09553009014551861

41. 

K NilssonL BjermerS HellströmA mast cell secretagogue, compound 48/80, prevents the accumulation of hyaluronan in lung tissue injured by ionizing irradiationAm J Respir Cell Mol Biol2199205199010.1165/ajrcmb/2.2.199

42. 

PL BollykyBA FalkRP WuIntact extracellular matrix and the maintenance of immune tolerance: high molecular weight hyaluronan promotes persistence of induced CD4+CD25+ regulatory T cellsJ Leukoc Biol86567572200919401397

43. 

L BoldrupPJ CoatesG LaurellK NylanderDifferences in p63 expression in SCCHN tumours of different sub-sites within the oral cavityOral Oncol47861865201110.1016/j.oraloncology.2011.07.00221802344

Related Articles

Journal Cover

December 2012
Volume 4 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Jonsson EL, Nylander K, Hallén L and Laurell G: Effect of radiotherapy on expression of hyaluronan and EGFR and presence of mast cells in squamous cell carcinoma of the head and neck. Oncol Lett 4: 1177-1182, 2012
APA
Jonsson, E.L., Nylander, K., Hallén, L., & Laurell, G. (2012). Effect of radiotherapy on expression of hyaluronan and EGFR and presence of mast cells in squamous cell carcinoma of the head and neck. Oncology Letters, 4, 1177-1182. https://doi.org/10.3892/ol.2012.907
MLA
Jonsson, E. L., Nylander, K., Hallén, L., Laurell, G."Effect of radiotherapy on expression of hyaluronan and EGFR and presence of mast cells in squamous cell carcinoma of the head and neck". Oncology Letters 4.6 (2012): 1177-1182.
Chicago
Jonsson, E. L., Nylander, K., Hallén, L., Laurell, G."Effect of radiotherapy on expression of hyaluronan and EGFR and presence of mast cells in squamous cell carcinoma of the head and neck". Oncology Letters 4, no. 6 (2012): 1177-1182. https://doi.org/10.3892/ol.2012.907